ALR Technologies Inc. (OTCMKTS:ALRT) Stock Rallies: Company Releases Successful Preliminary Results
ALR Technologies Inc. (OTCMKTS:ALRT) was up 17% after announcing initial findings from the Non-Inferiority Study presently ongoing on the GluCurce Pet CGM.
Market Stats
On Monday, ALRT stock moved up 17.65% to $0.0500 with more than 7.4K shares, compared to its average volume of 88.59K shares. The stock moved within a range of $0.0400 – 0.0500 after opening trading at $0.0400.
ALR Technologies Announces Successful Preliminary Results for the GluCurve Pet CGM Non-Inferiority Study
Using chemical analyzers as a benchmark, the GluCurve has already outperformed the top veterinarian Blood Glucose Meter (BGM) and satisfied all of the ISO: 15197:2013 accuracy standards for human blood glucose meters.
In comparison to the popular pet BGM utilized by vets, the company is impressed with GluCurve’s precision. All through the trial, the platform supplied critical diagnostic data which would not have been obtained from a standard in-clinic glucose curve. In addition, GluCurve has the advantage of being administered at the clinic within minutes and the pet being returned home.
While the owner and pet go about their normal lives, GluCurve monitors blood glucose levels every 3 minutes for around 14 days. Compared to BGM, which collects 5 to 7 datasets across eight to12 hours in a clinical context, this has numerous advantages. So in the coming weeks, ALRT is worth watching.
Key Quote
“We are pleased with GluCurve’s accuracy as compared to the leading pet BGM used by veterinarians. The platform has provided valuable diagnostic information throughout the study that would not be available from traditional in-clinic glucose curve. A significant benefit of GluCurve is that it is applied in minutes in-clinic and the pet is sent home. GluCurve records blood sugar levels every 3 minutes for up to 14 days while the pet and owner go about their daily lives. This presents many benefits compared to BGM whereby 5 to 7 data points are collected over 8-12 hours in a clinical setting. The process of housing a pet in-clinic and drawing blood every 2 hours causes stress which elevates their blood glucose levels and is challenging for the clinic staff to undertake. As part of the study, GluCurve was able to document the impact on glucose levels from the stressful clinical experience required for BGM testing in real time,” said Joe Stern, Head of Animal Health at ALR Technologies.
Traders Corner
ALRT stock is trading below the 50-Day and 500-Day Moving averages of $0.0517 and $0.0566 respectively. However, the stock is trading above the 20-Day moving average of $0.0488.
